â– LECTURE OVERVIEW: Competitive inhibition is a classical mechanism where a structural analog of a substrate binds reversibly to the active site of an enzyme, reducing the rate of reaction.
â– ENZYMATIC KINETICS & PROPERTIES:
1. Active Site Competition: The inhibitor competes directly with the substrate for the unoccupied active site of the free enzyme (E), forming an inactive enzyme-inhibitor complex (EI).
2. Kinship with Substrate: Because the inhibitor binds at the same site, competitive inhibition can be completely overcome by increasing the substrate concentration. At exceptionally high substrate concentrations, substrate molecules outcompete inhibitor molecules, occupying all active sites.
3. Vmax Unchanged: Because high substrate concentrations fully overcome competitive inhibition, the maximum velocity (Vmax) of the reaction remains completely unchanged.
4. Km Increased: The apparent Michaelis constant (Km) increases. Because the inhibitor is present, a higher concentration of substrate is required to achieve half of the maximum velocity (1/2 Vmax), representing a decreased apparent affinity of the enzyme for its substrate.
â– THERAPEUTIC TARGETS & MANAGEMENT:
Primary pharmacological intervention aims to restore physiological homeostatic balance. This is achieved by either competitively blocking receptor sites, allosterically inhibiting enzymes, or supplementing missing metabolic products.
â– CRITICAL CARE MANAGEMENT PROTOCOL:
Continuous cardiopulmonary and metabolic monitoring is paramount during acute decompensation. Maintain strict control over fluid ratios and oxygenation parameters.
[HY-BOARD-1084]
🌟 Dynamic Clinical Key:
Statins (e.g., Atorvastatin, Rosuvastatin) are classic clinical examples of competitive reversible inhibitors. They structurally resemble HMG-CoA, competing for the active site of HMG-CoA Reductase (the rate-limiting enzyme in cholesterol synthesis) to lower systemic LDL production. Absolute contraindications include pregnancy, renal insufficiency, or concurrent use of metabolic inhibitors. Do not delay airway protection and resuscitation maneuvers for low-priority imaging.